logo
CRC signs carbon agreement for National Cement plant near Gorman

CRC signs carbon agreement for National Cement plant near Gorman

Yahoo03-03-2025
A cement plan on Kern's southern border is expected to become California's first to achieve carbon neutrality under an agreement announced Monday between local oil producer California Resources Corp. and its new customer National Cement Co. of California.
Plans call for the 60-year-old facility east of Gorman to transition to produce a less carbon-intensive type of cement while increasing the amount of fuel it sources from local ag waste. Byproduct carbon dioxide will then be transported for permanent burial in Kern County.
Funded in part by a half billion-dollar federal matching subsidy, the project known as Lebec Net Zero is partly a response to a 2021 state law, Senate Bill 596, requiring all cement used in California be net zero by 2045.
The project is expected to create 20 to 25 new jobs when it begins operation as soon as 2031, assuming it wins required approvals.
The memo of understanding the companies signed is another achievement for CRC's subsidiary Carbon TerraVault, which continues to lead Kern's and California's push for greater investment in carbon capture and sequestration. The deal announced Monday brings CTV's carbon management total from pending projects to 9 million metric tons per year of CO2.
CRC President and CEO Francisco Leon said in a news release the agreement underscores increasing demand for innovative decarbonization solutions in California industry.
"Achieving carbon neutrality in the cement industry requires bold action, and this partnership is a critical step in developing the state's first carbon capture, transport, and storage project for this essential sector," he stated.
In the same release, National Cement's CEO, Eric Holard, called the project exciting and transformative.
"We are making a significant investment because we believe in creating a cleaner future and bringing innovation to domestic manufacturing," he stated. "CTV's leadership in safe and responsible carbon management, combined with our strategic and operational alignment, provides a clear pathway for this project being successful.'
CRC confirmed Monday the project must receive a conditional use permit from the county of Kern and undergo an environmental review.
One improvement over National Cement's existing configuration is that the new version will create what's called limestone calcined clay cement, which uses less of the carbon-intensive industrial material called clinker. The U.S. Department of Energy says L3C, as the more climate friendly form is called, will also increase the final product's performance and durability.
Additionally, the project is seen as being more environmentally sustainable because it will reduce the plant's intake of non-biomass fuels such as tires, carpets and petroleum. It will do that because of the biomass-burning capabilities of new kiln technology planned to be installed at the site.
The federal government selected the project for financial support last year along with 32 others in hard-to-decarbonize industries like cement, steel and aluminum production. The Department of Energy called the National Cement project the first carbon capture and sequestration system of its kind in the country.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Business Wire

timea day ago

  • Business Wire

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. ('Agenus') (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upcoming milestones and potential breakthroughs in immuno-oncology. The session will conclude with a live Q&A. Speakers to Include: Garo H. Armen, PhD Founder, Chairman, CEO of Agenus Jennifer Buell, PhD CEO of MiNK Therapeutics/ Chair of Executive Committee of Agenus Richard M. Goldberg, MD Chief Development Officer of Agenus (joined May 2025) GI oncology expert with 40+ years in CRC research Nicholas C. DeVito, MD Assistant Professor of Medical Oncology at Duke University Primarily treats patients with CRC and gastroesophageal cancers Research focused on tumor immune evasion and immunotherapy Chris O'Callaghan, DVM, MSc, PhD, & Jonathan Loree, MD, MS, FRCPC (CCTG): Senior Investigators at Canadian Cancer Trials Group (CCTG) Stakeholder Briefing Details: Webcast Link | Audience Conference Call Registration Link | Conference ID: 73242 About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. About Botensilimab (BOT) Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to 'cold' tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. Approximately 1,200 patients have been treated across the botensilimab/balstilimab program in phase 1 and phase 2 clinical trials. For more information about botensilimab trials, visit About Balstilimab (BAL) Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the botensilimab and balstilimab clinical programs, expected trial initiations and regulatory plans, and the potential benefits of the combination therapy. Words such as 'may,' 'believes,' 'expects,' 'anticipates,' 'hopes,' 'intends,' 'plans,' 'forecasts,' 'estimates,' 'will,' 'potential,' 'game-changing,' 'curative,' and similar expressions are intended to identify forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Factors that could cause actual results to differ include, but are not limited to, those described under the 'Risk Factors' section of Agenus' most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Agenus cautions investors not to place undue reliance on forward-looking statements in this release, which speak only as of the date of this announcement. The company undertakes no obligation to update or revise these statements, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

BTIG Downgrades The Trade Desk (TTD) Stock to Neutral
BTIG Downgrades The Trade Desk (TTD) Stock to Neutral

Yahoo

time4 days ago

  • Yahoo

BTIG Downgrades The Trade Desk (TTD) Stock to Neutral

The Trade Desk, Inc. (NASDAQ:TTD) is one of the Reddit Stocks with the Highest Upside Potential. On August 8, BTIG downgraded the company's stock to 'Neutral' from 'Buy' and removed the price target after The Trade Desk, Inc. (NASDAQ:TTD) posted Q2 2025 earnings. The firm's earlier thesis around a Kokai-driven turnaround is not playing out, and BTIG anticipates the company's shares to remain muted amidst an increased level of uncertainty around the macro and agency backdrop. A large array of computer screens and tech equipment representing the technology company's self-service cloud-based platform. The Trade Desk, Inc. (NASDAQ:TTD) made strong progress in CTV, retail media, and the supply chain, strengthening the largest brands and agencies to reach audiences throughout the open internet. Amidst continued innovation in Kokai, higher adoption of OpenPath, and deeper partnerships throughout the ecosystem, the company continues to deliver strong value to its clients and helps to strengthen the open internet. The Trade Desk, Inc. (NASDAQ:TTD) injected AI across several parts of the system as the clients that have adopted Kokai saw significant performance improvements. In the aggregate, The Trade Desk, Inc. (NASDAQ:TTD) continues to see over a 20-point improvement throughout key KPIs for campaigns running in Kokai. Baron Funds, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'The Trade Desk, Inc. (NASDAQ:TTD) is the leading internet advertising demand-side platform, enabling agencies to efficiently purchase digital advertising across PC, mobile, and online video channels. Shares fell on an earnings miss for the first time in 33 quarters. We believe the miss was due largely to a company reorganization in December and delays in its Kokai platform rollout, both of which we believe have since improved. We believe Trade Desk still represents the best option for biddable Connected TV (CTV) inventory. We note Trade Desk gained share against the incumbent Google in the last five years, even when Google charged low/no fees, and major companies like Netflix, Disney, and Spotify have opened their ad inventory to Trade Desk. Its market remains large and underpenetrated, as the shift to CTV advertising is still in the early stages. We believe Trade Desk can grow its top line by high teens to 20% year-over-year for years to come.' While we acknowledge the potential of TTD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

CleanTech Announces Intention to Amend Option Terms
CleanTech Announces Intention to Amend Option Terms

Yahoo

time6 days ago

  • Yahoo

CleanTech Announces Intention to Amend Option Terms

Vancouver, British Columbia--(Newsfile Corp. - August 14, 2025) - CleanTech Vanadium Mining Corp. (TSXV: CTV) (OTCQB: CTVFF) (FSE: C9R) ("CleanTech" or the "Company") announces that it proposes to reprice (the "Option Repricing") an aggregate of 9,090,000 incentive stock options of the Company (the "Options"). The Company intends to adjust the exercise price of 3,050,000 Options from $0.20 to $0.06, 4,030,000 Options from $0.18 to $0.06, 880,000 Options from $0.135 to $0.06, 100,000 Options from $0.16 to $0.06 and 1,030,000 Options from $0.10 to $0.06. The new exercise price in respect of the Options is set at the closing price of the common shares of the Company on August 13, 2025. An aggregate of 8,230,000 Options subject to the Option Repricing are held by insiders of the Company (the "Insider Options"). The completion of the Option Repricing is subject to, among other things, the approval of the TSX Venture Exchange ("TSXV"). Additionally, in accordance with the policies of the TSXV, repricing of the Insider Options is subject to disinterested shareholder approval in accordance with TSXV Policy 4.4 - Security Based Compensation. The purpose of the Option Repricing is primarily to encourage the early exercise of such Options. Related Party Transaction Certain of the directors, officers and other related parties of the Company hold an aggregate of 8,230,000 Options subject to the Option Repricing. Accordingly, the repricing of Options held by related parties of the Company is expected to constitute a "related party transaction" of the Company under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). It is expected that pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, the Company will be exempt from obtaining a formal valuation and minority approval of the Company's shareholders as the fair market value of repriced Options held by related parties of the Company is expected to be below 25% of the Company's market capitalization as determined in accordance with MI 61-101. A material change report including details with respect to the related party transaction may be filed less than 21 days prior to the closing of the Option Repricing as the Company wishes to complete such transactions in a timely manner. About CleanTech Vanadium Mining Corp. CleanTech is a mining company focused on critical mineral resources in the USA. The Company has an option to acquire 7,180 acres of mineral rights with historic Fluorspar resources across multiple projects in Illinois-Kentucky Fluorspar district. CleanTech also owns a 100% interest in the Gibellini Vanadium Mine Project in Nevada. Further information on CleanTech can be found at ON BEHALF OF THE BOARD "John Lee" Chief Executive Officer For more information about CleanTech, please contact: Phone: 1.877.664.2535Email: info@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store